![](https://ml.globenewswire.com/media/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8/small/ascendis-final-logo-7-23-15-png.png)
Ascendis Pharma Reports Second Quarter 2024 Financial Results
YORVIPATH approved by U.S. Food & Drug Administration (FDA) as the first and only treatment of hypoparathyroidism in adults TransCon CNP (navepegritide) pivotal ApproaCH Trial topline results expected in the coming weeks SKYTROFA Q2 revenue of €26 …